A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide Extended-release for Injectable Suspension, 1 mg

Singel-dose; Subcutaneous

DRUG

Semaglutide Extended-release for Injectable Suspension, 4 mg

Singel-dose; Subcutaneous

DRUG

Semaglutide Extended-release for Injectable Suspension, 8 mg

Singel-dose; Subcutaneous

All Listed Sponsors

lead

Bostal Drug Delivery Co., Ltd

INDUSTRY